{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:40:28Z","timestamp":1769078428523,"version":"3.49.0"},"reference-count":39,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Evaluation Clinical Practice"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients suffering from multidrug\/rifampicin resistant tuberculosis (MDR\/RR\u2010TB) are treated for prolonged periods with a complex regimen comprised of relatively less effective and more toxic anti\u2010TB drugs, consequently resulting in high incidence of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Aim<\/jats:title>\n                    <jats:p>The current study evaluates the incidence, types, management and predictors of AEs, and their impact on treatment outcomes in MDR\/RR\u2010TB patients receiving all oral treatment regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>A total of 242 eligible MDR\/RR\u2010TB patients treated at two different study sites from June 2019 to December 2021 were included in this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measures and Outcomes<\/jats:title>\n                    <jats:p>Patients' sociodemographic, microbiological, clinical characteristics, reported AEs and treatment outcomes were retrospectively abstracted from their medical records. Chi\u2010square, and Fisher exact tests (wherever applicable) were used to find the association between the variable and the occurrence of AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Majority of the patients were suffered from MDR\u2010TB (71.9%) and were treated with longer treatment regimen (77.7%). Overall 206\/242 patients (85%) experienced at least one AE during their treatment. Gastrointestinal disturbance was the most common AE (49.6%), followed by arthralgia (49.2%), psychiatric disturbances (39.3%), dermatological reactions (27.7%), body\/headache (24.8%) and hyperuricemia (19%). Due to AEs, treatment modification was noted in 55 (22.72%) patients. Level of modification in the treatment regimen was higher in optic neuritis (100%) followed by neuropathies (80%) and myelosuppression (59%). Similarly, hepatotoxicity was the most serious AE in which the whole treatment regimen was terminated in 27% of patients. Furthermore, the results revealed that only patients' education status had statistically significant association with the incidence of AEs (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). The treatment success rate was 80.6% whereas the ratio of died and LTFU patients were 15.3% and 4.1% respectively. Although patients who experienced AEs were more likely to develop successful treatment outcomes (82%) than their counterparts (72.2%), though this difference was not statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although AEs were highly present in the current cohort, but they were successfully managed mostly by nonpharmacological interventions or symptomatic treatment. Besides, the incidence of AEs did not have a negative impact on treatment outcomes. High\u2010risk patients for AEs must receive special attention and enhanced clinical management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jep.14230","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T06:49:40Z","timestamp":1730702980000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incidence, types and predictors of adverse events and their impact on treatment outcomes in multidrug\/rifampicin resistant tuberculosis patients receiving all oral treatment regimens"],"prefix":"10.1111","volume":"31","author":[{"given":"Sayed Idrees","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Pharmacy Shaheed Benazir Bhutto University Sheringal Pakistan"},{"name":"Programmatic Management of Drug Resistant TB Unit Saidu Group of Teaching Hospitals Swat Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Ghafoor","sequence":"additional","affiliation":[{"name":"National TB Control Program Islamabad Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0162-4478","authenticated-orcid":false,"given":"Shafiq Ur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shaheed Benazir Bhutto University Sheringal Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Abidullah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shaheed Benazir Bhutto University Sheringal Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nafees","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy and Health Sciences University of Baluchistan Quetta Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6342-6573","authenticated-orcid":false,"given":"Ayman M.","family":"Al\u2010Qaaneh","sequence":"additional","affiliation":[{"name":"Department of Allied Health Sciences Al\u2010Balqa Applied University (BAU) Al\u2010Salt Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Younis","sequence":"additional","affiliation":[{"name":"Association for Community Development Khyber Pakhtunkhwa Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0167"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31644-1"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30047-3"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000421"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159560"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00044812"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/2052-3211-7-14"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0091-1"},{"issue":"12","key":"e_1_2_10_11_1","first-page":"1373","article-title":"Side effects associated with the treatment of multidrug\u2010resistant tuberculosis","volume":"9","author":"T\u00f6r\u00fcn T","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mjt.0000433951.09030.5a"},{"key":"e_1_2_10_13_1","volume-title":"WHO Guidelines Approved by the Guidelines Review Committee, in WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment\u2014Drug\u2010Susceptible Tuberculosis Treatment","author":"World Health Organization \u00a9 World Health Organization 2022","year":"2022"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-1134"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.640555"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2016.07.026"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2019.04.009"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/trstmh\/traa040"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0936"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2746-5"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151321"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.883483"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2016.01.031"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.4236\/jtr.2021.92008"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.876955"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.5958\/0976-5506.2018.00032.3"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.4236\/jtr.2014.23018"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.790718"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1806-4"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.904682"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dialog.2023.100115"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.53350\/pjmhs2023171752"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijcm.IJCM_813_21"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2020.100200"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz914"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08085-3"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq017"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm89020019"},{"issue":"1","key":"e_1_2_10_39_1","first-page":"27","article-title":"Orofacial manifestations of adverse drug reactions: a review study","volume":"91","author":"Bakhtiari S","year":"2018","journal-title":"Clujul Med (1957)"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmy.ijmy_176_21"}],"container-title":["Journal of Evaluation in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jep.14230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:14:49Z","timestamp":1763446489000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jep.14230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/jep.14230"],"URL":"https:\/\/doi.org\/10.1111\/jep.14230","archive":["Portico"],"relation":{},"ISSN":["1356-1294","1365-2753"],"issn-type":[{"value":"1356-1294","type":"print"},{"value":"1365-2753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"2024-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14230"}}